SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
FDA Calendar Updates: KG, PTIE, DRRX, ALTH, TRIB, CBST, DYAX
KG
|
|
|
+18.25%
in
125 days
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 243 entries as of 7/7/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending...
|
FDA Calendar Updates: ACUR, KG, MYRX, NEPH, Eisai
KG
|
|
|
-1.56%
in
5 days
(closed on 07/07/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st...
|
FDA Calendar Updates: Royal Returns for King Pharma
KG
|
|
|
+4.45%
in
52 days
(closed on 07/02/09)
<> Below is a summary of updates to the <font> BioMedReports.com </font> database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions...
|
BioMed Stock Movers: DNDN, EXAS, KG
KG
|
|
|
+20.21%
in
33 days
(closed on 05/11/09)
Dendreon (DNDN) has stalled out around $6.50 per share after a major rally on news of upcoming presentation at a medical conference later this month. DNDN expects to report Provenge clinical trial results some time before the end of April, although it did not guarantee this would occur at the upcoming presentation. The recent spike in shares of DNDN and upcoming presentation do not provide any clarity on whether Provenge results will be sufficient for attaining FDA approval and the pending data release will determine the Company's fate. <> <> <>http://biomedreports.com/article...
|
King Pharma: A Value Play on New Drug Approvals
KG
|
|
|
+11.00%
in
20 days
(closed on 04/08/09)
King Pharma (KG) is a specialty pharmaceutical company which recently acquired Alpharma for $1.6B and has three pending NDAs at the FDA for new drug approvals and received a complete response late last year for Remoxy (an abuse deterrent form of extended-release oxycodone) along with Pain Therapeutics (PTIE). BioMedReports.com FDA and Clinical Trial Calendars: <> King is currently trading at around decade lows in terms of stock price at a market cap of $1.7B and enterprise value of $2.2B. Consensus analyst est...
|
From the Blogosphere
King Beats, but Earnings Down – Analyst Blog
|
|
|
King Pharmaceuticals, Inc. (KG) reported third quarter earnings of 29 cents per share, beating the Zacks Consensus Estimate by 2 cents. Despite revenues increasing 19.3% from the year-ago period, earnings declined 25.6% from the year-ago quarter mainly due to higher operating expenses.
Total revenues came in at $463.3 million. The primary growth drivers were the Animal Health business, which came as a part of the Alpharma acquisition and an increase in sales of auto-injectors in the Meridian business.
King’s branded pharmaceuticals segment posted revenues of $283 million, down 6.3% from the p< />< /><><><><>< />< /><>< />< />< />< />< />< />< />< />< />< /><><>< /><>< /><>< /><>< /><>< /><>< /><>< /><><>< /><>< /><>< />< />...
|
Stock of the Week Adds Another 8%
Monday morning we recommended King Pharmaceuticals (KG) as our stock of the week. The recommendation was distributed at 8:30 and we calculate performance based on the opening that day. Subscribers to Birinyi's Mini-Institutional service have gained 7.7% through Wednesday's close,...
|
Chou Funds 2009 Semi-Annual Report Available
<>Francis Chou has posted his semi-annual report on his website. I pay most attention to his shareholder letter for the flagship Chou Associates Fund, because the other fund letters are based on it. <>As I repeatedly say, reading the thoughts of value managers like Chou and Tim McElvaine and a few others is more fruitful than Warren Buffett. That is NO slam at Buffett. If you're a regular Controlled Greed reader, you know reading Buffett's "Superinvestors of Graham and Doddsville" in 1986 was a formative event in my (financial) life. But the massive size of Berkshire Hathaway limits his stock-pi...
|
Notable Analyst Rating Changes 8/7: KNOT, KG, CROX Upgraded; RIG, CMCSA, ZLC Downgraded
UPGRADES:Stifel Nicolaus upgrades The Knot (Nasdaq: KNOT) from Hold to Buy. Price target $11. Bank of America upgrades King Pharmaceuticals (NYSE: KG) from Neutral to Buy. Price target increased $4 to $14. Piper Jaffray upgrades Crocs (Nasdaq: CROX) from Neutral to Overweight, following better than expected results after the close. The firm said global demand drives the path to profit in 2010. The firm also raised their price target from $3 to $7.50. See full report here.For daily real-time Upgrades go to http://www.streetinsider.com/UpgradesDOWNGRADES:Calyon Securities downgrades Transoce...
|
Analyst upgrades, downgrades and initiations: ACI, CMCSA, DF, HPQ, LEAP, ZLC ...
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
More Resources
|
About King Pharmaceuticals Inc.
- Answers.com
